Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial

Lancet

Volumn 356, Issue 9227, 2000, Pages 385-390

  Mease, Philip J ^a   Goffe, Bernard S ^a   Metz, James ^a   Vanderstoep, Ann ^a   Finck, Barbara ^a   Bürge, Daniel J ^a  

^a Minor and James Medical   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; ETANERCEPT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0034729950     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02530-7     Document Type: Article

References (30)

1. Greaves MW, Weinstein GD. Drug therapy: treatment of psoriasis. N Engl J Med 1995; 332: 581-88.
2. Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaquetype psoriasis: results of a multidose, double-blind trial. N Engl J Med 1991; 324: 277-84.
3. Roenigk HH Jr, Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conférence. J Am Acad Dermatol 1998; 38: 479-85.
4. Spadaro A, Taccari E, Mohtadi B, Riccieri F, Sensi F, Zoppini A. Life-table analysis of cyclosporin A treatment in psoriatic arthritis: comparison with other disease-modifying antirheumatic drugs. Clin ExpRheumatol 1997; IS: 609-14.
5. Lebwohl M, Ellis C, Gottlieb A, et al. Cyclosporin consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998; 39: 464-75.
6. Stem RS. Epidemiology of cutaneous diseases. In: Fitzpatrick TB, ed. Textbook of General Medicine. New York: McGraw Hill, 1987: 6-10.
7. Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55-78.
8. Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez Larrea C. Psoriatic arthritis: a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991; 30: 245-50.
9. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA)-an analysis of 220 patients. Q J Med 1987;62: 127-41.
10. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center-II: prognostic indicators for death. Arthritis Rheum 1998; 41: 1 103-10.
11. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic-I: causes and risk of death. Arthritis Rheum 1997; 40: 1868-72.
12. Espinoza LR, Cuellar ML. Psoriatic arthritis: management. In: Kippel J, Dieppe P, eds. Rheumatology. London: Mosby Year Book Europe Limited, 1994; 3: 33-1-33-6.
13. Jones G, Crotty M, Brooks P, the Psoriatic Arthritis Meta-Analysis Study Group. Psoriatic arthritis: a quantitative overview of therapeutic options. Br J Rheumatol 1997; 36: 95-99.
14. Pioro MH, CashJM. Treatment of refractory psoriatic arthritis. Rheum Dis Clin North Am 1995; 21: 129-49.
15. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. Arthritis Rheum 1996; 39: 2013-20.
16. Farr M, Kitas GD, Waterhouse L, Jubb R, Felix-Davies D, Beacon PA. Sulfasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br J Rheumatol 1990; 29: 46-49.
17. Cuellar ML, Espinoza LR. Methotrexate use in psoriasis and psoriatic arthritis. Rheum Dis Clin North Am 1997; 23: 797-809.
18. Black RL, O'Brien WM, Van Scott EJ, Auerbach R, Eisen AZ, Bunim JJ. Methotrexate therapy in psoriatic arthritis. JAMA 1 964; 189: 743-47.
19. Willkens RF, Williams HJ, Ward JR, et al. Randomized, doubleblind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984; 27: 376-81.
20. Palit J, Hill J, Capell HA, et al. A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate, and placebo in patients with psoriatic arthritis. Br J Rheumatol 1990; 29: 280-83.
21. Partsch G, Steiner G, Leeb BF, Dunky A, Broil H, Smolen JS. Highly increased levels of tumor necrosis factor-a and other proinfiammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24: 518-23.
22. Partsch G, Wagner E, Leeb BF, Dunky A, Steiner G, Smolen JS. Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid. J Rheumatol 1998; 25: 105-10.
23. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998; 25: 1544-52.
24. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RDR. Elevated tumour necrosis factor-alpha (TNF-a) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-51.
25. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomised, controlled trial. Ann Intern Med 1999; 130: 478-86.
26. Fredricksson T, Petersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
27. Felson DT, Andersen JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
28. Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity: II. Effect of arninopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951; 221: 176-82.
29. O'Brien WM, Van Scott EJ, Black R, Eisen AZ, Bunim JJ. Clinical trial of arnethopterin (methotrexate) in psoriatic and rheumatoid arthritis (preliminary report). Arthritis Rheum 1962; 5: 312.
30. Weinblatt ME, Kremer KM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-59.